Femtobiomed is a cell engineering device manufacturing company built upon CellShot®, employing the patented ‘Partitioned Flow Transfection’. Using a multiple port cartridge, the customised mRNA is separately delivered and transfected to a targeted human primary hematopoietic cell at an optimal environment for a brief harvest prior to injection. With CellShot®, the development of novel therapies will be accelerated by immensely simplifying the existing non-viral approaches, along with significantly improved efficiency and yield. Ultimately, our patented platform instrument can provide innovative cell therapeutic options to the patient in affordable ways.